



## Issuance of Convertible Notes and Options Under the Tranche 1 Offer

**San Diego, California and Sydney, Australia (Friday, 5 May 2017, AEST)** – REVA Medical, Inc. (ASX: RVA) (“REVA” or the “Company”) announces that 338 convertible notes with a face value of US\$100,000 each and 1,521,000 options to purchase 1,521,000 shares of common stock have been issued. These issuances were made pursuant to the Tranche 1 Offer under the Prospectus lodged with the Australian Securities Exchange and the Australian Securities and Investments Commission on 24 April 2017 (the “Prospectus”) and in accordance with the Convertible Note Deed dated 22 April 2017. The Tranche 1 Offer under the Prospectus has now closed. Details of the issuances are provided in the attached Appendix 3B.

### About REVA

REVA is a medical device company located in San Diego, California, USA, that has developed a proprietary bioresorbable scaffold, as an alternative to metal stents, to treat coronary artery disease. Scaffolds provide restoration of blood flow, support the artery through the healing process, then disappear (or “resorb”) from the body over a period of time. This resorption allows the return of natural movement and function of the artery, a result not attainable with permanent metal stents. The Company’s *Fantom*<sup>®</sup> scaffold has been designed to offer an ideal balance of thinness and strength, with distinct ease-of-use features including complete scaffold visibility under x-ray, expansion with one continuous inflation, and no procedural time limitations.

### Forward-Looking Statements

*This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management. All statements that are not statements of historical fact, including those statements that address future operating performance and events or developments that we expect or anticipate will occur in the future, are forward-looking statements, such as those statements regarding our ability to commercialize current products, develop and commercialize new products, timely and successfully complete clinical trials, obtain additional regulatory approvals, protect our intellectual property position, recruit and retain key personnel, and estimates regarding our capital requirements and financial performance. Readers should not place undue reliance on forward-looking statements. Although management believes forward-looking statements are reasonable as and when made, forward-looking statements are subject to a number of risks and uncertainties that may cause actual results to vary materially from those expressed in forward-looking statements, including the risks and uncertainties that are described in the "Risk Factors" section of our Annual Report on Form 10-K filed with the US Securities and Exchange Commission (the "SEC") on February 28, 2017. Any forward-looking statements in this announcement speak only as of the date when made. REVA does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.*

**United States  
Investor & Media Enquiries:**  
REVA Medical, Inc.  
Cheryl Liberatore  
Director, Communications  
+1 858-966-3045

**Australia  
Investor Enquiries:**  
Inteq Limited  
Kim Jacobs  
+61 438 217 279  
Andrew Cohen  
+61 408 333 452

**Australia  
Media Enquiries:**  
Buchan Consulting  
Rebecca Wilson  
+61 3 9866 4722

# Appendix 3B

## New issue announcement, application for quotation of additional securities and agreement

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name of entity

REVA Medical, Inc.

ARBN

146 505 777

We (the entity) give ASX the following information.

### Part 1 - All issues

*You must complete the relevant sections (attach sheets if there is not enough space).*

- |   |   |   |
|---|---|---|
| 1 | +Class of +securities issued or to be issued  | 1) Issuance of convertible notes (unquoted).<br>2) Issuance of options (unquoted).  |
| 2 | Number of +securities issued or to be issued (if known) or maximum number which may be issued   | 1) 338 convertible notes.<br>2) 1,521,000 options to purchase 1,521,000 shares of common stock (equivalent to 15,210,000 CDIs).   |
| 3 | Principal terms of the +securities (e.g. if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion) | Convertible notes and options issued under the Convertible Note Deed dated 22 April 2017 (the "Note Deed"):<br>1) 338 convertible notes, each with a face value of US\$100,000 (a summary of the terms were disclosed to the market on 24 April 2017, including a summary of the conversion price and dates for conversion).<br>2) 1,521,000 options exercisable at any time into common stock for either (a) US\$5.00 per share before an IPO or Subsequent Financing (as defined in the Note Deed), or, (b) the greater of the applicable Subsequent Financing Price or IPO Price (but in no event to exceed US\$7.212 per share) or US\$5.00 per share, after an IPO or Subsequent Financing. Options expire five years after issuance if not exercised. The full terms on which the options are being issued were lodged with ASX on 24 April 2017. |

+ See chapter 19 for defined terms.

For personal use only

4	<p>Do the <sup>+</sup>securities rank equally in all respects from the <sup>+</sup>issue date with an existing <sup>+</sup>class of quoted <sup>+</sup>securities?</p> <p>If the additional <sup>+</sup>securities do not rank equally, please state:</p> <ul style="list-style-type: none"> <li>• the date from which they do</li> <li>• the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment</li> <li>• the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment</li> </ul>	<p>No.</p> <ol style="list-style-type: none"> <li>1) Convertible notes are not entitled to any rights of stockholders.</li> <li>2) Options are not entitled to any rights of stockholders.</li> </ol>
5	Issue price or consideration	<ol style="list-style-type: none"> <li>1) Convertible notes for total consideration of US\$33,800,000.</li> <li>2) No monetary consideration is payable for the issuance of the options.</li> </ol>
6	<p>Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)</p>	<p>Issuance of convertible notes to provide US\$21,306,941 cash proceeds to fund the future operations of the Company, expenses of the offer, and US\$12,493,059 cash proceeds that will be used to repurchase 1,732,260 shares of the Company's common stock at a price of US\$7.212 per share; further details are set out in sections 1.11 and 2.4 of the Prospectus for the offer, which was lodged with ASX on 24 April 2017.</p>
6a	<p>Is the entity an <sup>+</sup>eligible entity that has obtained security holder approval under rule 7.1A?</p> <p>If Yes, complete sections 6b – 6h <i>in relation to the <sup>+</sup>securities the subject of this Appendix 3B</i>, and comply with section 6i</p>	<p>Not applicable.</p>
6b	The date the security holder resolution under rule 7.1A was passed	<p>Not applicable.</p>
6c	Number of <sup>+</sup> securities issued without security holder approval under rule 7.1	<p>Not applicable.</p>
6d	Number of <sup>+</sup> securities issued with security holder approval under rule 7.1A	<p>Not applicable.</p>
6e	Number of <sup>+</sup> securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	<p>Not applicable.</p>
6f	Number of <sup>+</sup> securities issued under an exception in rule 7.2	<p>Not applicable.</p>
6g	<p>If <sup>+</sup>securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the <sup>+</sup>issue date and both values. Include the source of the VWAP calculation.</p>	<p>Not applicable.</p>

+ See chapter 19 for defined terms.

6h If +securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements

	Not applicable.
--	-----------------

6i Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements

	Not applicable.
--	-----------------

7 +Issue dates

Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A. Cross reference: item 33 of Appendix 3B.

	Convertible notes and options issued 5 May 2017.
--	--

	Number	+Class
8 Number and +class of all +securities quoted on ASX (including the +securities in section 2 if applicable)	428,514,770 CDIs are quoted, assuming all shares of common stock are held as CDIs (a total of 42,851,477 common shares are issued and outstanding).	CDIs

	Number	+Class
Number and +class of all +securities not quoted on ASX (including the +securities in section 2 if applicable)	422,925 options (over 422,925 shares of common stock or 4,229,250 CDIs).	Options issued under the 2001 Stock Option/Stock Issuance Plan.
	6,121,367 options (over 6,121,367 shares of common stock or 61,213,670 CDIs).	Options issued under the Amended and Restated 2010 Equity Incentive Plan.
	929,550 RSUs (over 929,550 shares of common stock or 9,295,500 CDIs).	RSUs issued under the Amended and Restated 2010 Equity Incentive Plan.
	250 convertible notes.	Convertible notes issued under Convertible Note Deed dated 25 September 2014.
	338 convertible notes.	Convertible notes issued under Convertible Note Deed dated 22 April 2017.
	1,521,000 options (over 1,521,000 shares of common stock or 15,210,000 CDIs).	Options issued under Convertible Note Deed dated 22 April 2017.

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

	Not applicable.
--	-----------------

+ See chapter 19 for defined terms.

## Part 2 - Pro rata issue

11	Is security holder approval required?	Not applicable.
12	Is the issue renounceable or non-renounceable?	Not applicable.
13	Ratio in which the +securities will be offered	Not applicable.
14	+Class of +securities to which the offer relates	Not applicable.
15	+Record date to determine entitlements	Not applicable.
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	Not applicable.
17	Policy for deciding entitlements in relation to fractions	Not applicable.
18	Names of countries in which the entity has security holders who will not be sent new offer documents <small>Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7.</small>	Not applicable.
19	Closing date for receipt of acceptances or renunciations	Not applicable.
20	Names of any underwriters	Not applicable.
21	Amount of any underwriting fee or commission	Not applicable.
22	Names of any brokers to the issue	Not applicable.
23	Fee or commission payable to the broker to the issue	Not applicable.
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	Not applicable.
25	If the issue is contingent on security holders' approval, the date of the meeting	Not applicable.
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	Not applicable.
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	Not applicable.
28	Date rights trading will begin (if applicable)	Not applicable.
29	Date rights trading will end (if applicable)	Not applicable.
30	How do security holders sell their entitlements <i>in full</i> through a broker?	Not applicable.
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	Not applicable.

+ See chapter 19 for defined terms.

For personal use only

32 How do security holders dispose of their entitlements (except by sale through a broker)? Not applicable.

33 +Issue date Not applicable.

### Part 3 - Quotation of securities

*You need only complete this section if you are applying for quotation of securities*

34 Type of +securities  
(tick one)

(a)  +Securities described in Part 1

(b)  All other +securities  
Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

#### Entities that have ticked box 34(a)

##### Additional securities forming a new class of securities

*Tick to indicate you are providing the information or documents*

35  If the +securities are +equity securities, the names of the 20 largest holders of the additional +securities, and the number and percentage of additional +securities held by those holders

36  If the +securities are +equity securities, a distribution schedule of the additional +securities setting out the number of holders in the categories  
1 - 1,000  
1,001 - 5,000  
5,001 - 10,000  
10,001 - 100,000  
100,001 and over

37  A copy of any trust deed for the additional +securities

#### Entities that have ticked box 34(b)

38 Number of +securities for which +quotation is sought Not applicable.

39 +Class of +securities for which quotation is sought Not applicable.

40 Do the +securities rank equally in all respects from the +issue date with an existing +class of quoted +securities? Not applicable.

If the additional +securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

+ See chapter 19 for defined terms.

For personal use only

41 Reason for request for quotation now  
 Example: In the case of restricted securities, end of restriction period  
 (if issued upon conversion of another +security, clearly identify that other +security)

Not applicable.
-----------------

42 Number and +class of all +securities quoted on ASX (including the +securities in clause 38)

Number	+Class
Not applicable.	Not applicable.

**Quotation agreement**

1 +Quotation of our additional +securities is in ASX’s absolute discretion. ASX may quote the +securities on any conditions it decides.

2 We warrant the following to ASX.

- The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
- There is no reason why those +securities should not be granted +quotation.
- An offer of the +securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any +securities to be quoted and that no-one has any right to return any +securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the +securities be quoted.
- If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the +securities be quoted.

3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.

4 We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before +quotation of the +securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: .....  
 (Company Secretary)

Date: 5 May 2017

Print name: Katrina L. Thompson

== == == == ==

+ See chapter 19 for defined terms.

For personal use only